STERIS (STE) Expected to Announce Quarterly Earnings on Monday

STERIS (NYSE:STE) is expected to announce its Q4 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of $2.86 per share and revenue of $1.5946 billion for the quarter. Investors can find conference call details on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 9:00 AM ET.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. STERIS’s revenue was up 9.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.32 EPS. On average, analysts expect STERIS to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

STERIS Stock Performance

Shares of NYSE:STE opened at $207.40 on Friday. The company’s 50 day simple moving average is $224.30 and its 200 day simple moving average is $244.27. The stock has a market capitalization of $20.34 billion, a price-to-earnings ratio of 28.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. STERIS has a 1 year low of $195.14 and a 1 year high of $269.44.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Investors of record on Monday, June 8th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Monday, June 8th. STERIS’s dividend payout ratio (DPR) is 35.15%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on STE shares. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Weiss Ratings cut shares of STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, April 16th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $275.20.

Insider Activity at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of STERIS stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the transaction, the director owned 705 shares in the company, valued at approximately $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.07% of the company’s stock.

Hedge Funds Weigh In On STERIS

A number of hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. lifted its holdings in STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 104 shares during the period. Kemnay Advisory Services Inc. acquired a new position in STERIS in the fourth quarter valued at $34,000. DV Equities LLC acquired a new position in STERIS in the fourth quarter valued at $35,000. Advisory Services Network LLC acquired a new position in STERIS in the third quarter valued at $68,000. Finally, MUFG Securities EMEA plc acquired a new position in STERIS in the second quarter valued at $69,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.